文献速递内脏/肾动脉与血管畸形

88例血管型埃勒斯-当洛斯综合征患者脾动脉病变的表现、手术干预与结局

Splenic artery pathology presentation, operative interventions, and outcomes in 88 patients with vascular Ehlers-Danlos syndrome.
PubMed 文献 · J Vasc Surg · 2023-04-15

该横断面分析纳入1547例经基因确诊的血管型埃勒斯-当洛斯综合征(VEDS)患者,其中88例(5.7%)存在脾动脉病变,47%以破裂为首发表现,总破裂率达51%。开放手术与高并发症和死亡相关,而栓塞 outcomes 良好;作者建议脾动脉瘤直径达15 mm时考虑修复,并需长期随访。

要点

  • VEDS患者中脾动脉病变占5.7%,47%以破裂为首发表现,总破裂率51%。
  • 开放修复出现4例术中死亡及血管瘘、肠或胰腺损伤等并发症,栓塞无死亡或入路部位并发症。
  • 作者建议脾动脉瘤直径达15 mm时考虑修复,栓塞后23.5%患者残余脾动脉出现新发动脉瘤,需长期随访。

核心结论

  • VEDS中的脾动脉病变与影响III型胶原结构和分泌的变异相关,且常以破裂起病。
  • 破裂和开放修复与高发病率和高死亡率相关,而栓塞与良好结局相关。
  • 作者建议脾动脉瘤直径达15 mm时考虑修复,并指出需长期随访,因为可发生继发性脾动脉病变。

研究设计与样本

  • 对1547例经基因确诊VEDS(致病性COL3A1变异)患者进行横断面分析,数据来自三个重叠队列:VEDS协作自然史研究(N=242)、单中心队列(N=75)和华盛顿大学胶原诊断实验室队列(N=1231),去除重复后纳入有脾动脉瘤、假性动脉瘤、夹层、血栓形成或破裂的患者。

主要发现

  • 88例患者于1992年至2021年间就诊,占队列的5.7%;诊断时平均年龄37±11.1岁,50%为男性。
  • 三分之一患者在脾动脉病变诊断前已确诊VEDS,17%为死后诊断;61%有阳性家族史,71.6%的COL3A1变异与极少的正常胶原产生相关。
  • 中位随访8.5年(四分位距0.9-14.7年);47%以破裂为首发表现,总脾动脉破裂率为51%(n=45),包括4例脾破裂。
  • 39%的病例发现脾动脉瘤;仅12例记录了脾动脉直径,中位直径12 mm(四分位距10.3-19.3 mm)。
  • 34例患者(38.6%)接受了40次脾动脉干预:21次开放手术、18次栓塞、1次未知手术;5例(14.7%)接受了不止一次脾动脉干预。

临床怎么用

  • 作者建议脾动脉瘤直径达15 mm时考虑修复。
  • 作者指出需长期随访,因为可发生继发性脾动脉病变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vascular Ehlers-Danlos syndrome (VEDS) is rare and associated with arteriopathies. The aim of this study is to investigate the presentation, operative interventions, and outcomes of splenic arterial pathology in a population of more than 1500 individuals with genetically confirmed VEDS due to pathogenic COL3A1 variants. METHODS: Cross-sectional analysis of 1547 individuals was performed. The data were assembled by harmonizing data from three overlapping cohorts with genetically confirmed VEDS: the VEDS Collaborative Natural History Study (N = 242), a single-center cohort (N = 75), and the University of Washington Collagen Diagnostic Lab cohort (N = 1231). Duplicates were identified and removed. Patients were selected for analysis if they had splenic artery aneurysm (SAA), pseudoaneurysm, dissection, thrombosis, or rupture. Demographics, COL3A1 variants, interventions, and outcomes were analyzed. Comparisons by splenic artery rupture were made. RESULTS: A total of 88 patients presented between 1992 and 2021 with splenic artery pathology (5.7% of the cohort; mean age at diagnosis, 37 ± 11.1 years; 50% male). One-third were diagnosed with VEDS prior to the splenic artery pathology diagnosis, and 17% were diagnosed post-mortem. Most had a positive family history (61%). Most had COL3A1 variants associated with minimal normal collagen production (71.6%). Median follow up was 8.5 years (interquartile range, 0.9-14.7 years). Initial presentation was rupture in 47% of the cases. Splenic artery rupture overall was 51% (n = 45), including four cases of splenic rupture. There were no major differences in VEDS-related manifestations or COL3A1 variant type by rupture status. SAA was noted in 39% of the cases. Only 12 patients had splenic artery diameter documented in 12 cases with a median diameter of 12 mm (interquartile range, 10.3-19.3 mm). A total of 34 patients (38.6%) underwent 40 splenic arterial interventions: 21 open surgical, 18 embolization, and one unknown procedure. More than one splenic artery intervention was performed in five cases (14.7%). Open repair complications included arteriovenous fistula (n = 1), intestinal or pancreatic injury (n = 1 each), and four intraoperative deaths. There were no deaths or access site complications related to splenic artery embolization. Four patients (23.5%) developed a new SAA in the remaining splenic artery post embolization. All-cause mortality was 35% (n = 31), including 22 related to a ruptured splenic artery. CONCLUSIONS: Splenic arteriopathy in VEDS is associated with variants that affect the structure and secretion of type III collagen and frequently present with rupture. Rupture and open repair are associated with high morbidity and mortality, whereas embolization is associated with favorable outcomes. Suggest repair considerations at SAA diameter of 15 mm. Long-term follow-up is indicated as secondary splenic arteriopathy can occur.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shalhub S, Nkansah R, El-Ghazali A, et al. Splenic artery pathology presentation, operative interventions, and outcomes in 88 patients with vascular Ehlers-Danlos syndrome. J Vasc Surg. 2023. PMID: 37068529. doi:10.1016/j.jvs.2023.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。